David Surguladze Email

VP Preclinical Pharmacology . HiberCell

Current Roles

Employees:
59
Revenue:
$4.6M
About
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As ᅢᄁ¬ツᆲᅤモthe dormancy company,ᅢᄁ¬ツᆲᅡン we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
HiberCell Address
619 West 54th Street
New York, NY
United States
HiberCell Email

Past Companies

HiberCellVice President Preclinical Pharmacology
Eli Lilly and CompanyDirector Preclinical Pharmacology
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and CompanyAssociate Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.